Business Context and Reporting Period
This Form 8-K is filed by Oculus Innovative Sciences, Inc. (not Sonoma Pharmaceuticals, Inc.) for the reporting period ending November 30, 2016. The filing primarily addresses Item 5.02 regarding the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. The company is based in Petaluma, California.
Key Financial Metrics and Compensation Details
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. Instead, it details specific compensation awards and employment terms:
- Stock Price: $4.81 per share (closing price on November 30, 2016).
- CEO Bonus (Jim Schutz): Total award of $57,000 for Fiscal Year 2016 ($40,000 cash, $17,000 in stock/3,535 shares) plus a $6,800 tax gross-up.
- CFO Bonus (Robert Miller): $75,000 in stock (15,593 shares) plus a $30,000 tax gross-up.
- Other Executive Bonuses:
- Robert Northey (EVP R&D): $40,000 cash, $22,500 stock (4,678 shares), $9,000 tax gross-up.
- Bruce Thornton (EVP Int'l Ops): $50,000 cash, $12,500 stock (2,599 shares), $5,000 tax gross-up.
- Signing Bonuses: CEO Jim Schutz and CFO Robert Miller each received options to purchase 50,000 shares (immediate vesting, $4.81 exercise price, expiring Nov 30, 2026).
- Asset Sale Context: Bonuses were awarded in part for building a business in Mexico, which was sold to Invekra, S.A.P.I de C.V. for $22 million in October 2016.
Material Changes Versus Prior Period
The filing outlines significant changes to executive compensation structures and employment terms effective November 30, 2016:
- Employment Agreements: New agreements were executed with the CFO, two Executive Vice Presidents, and the President of the IntraDerm division to eliminate outdated practices (e.g., automatic vesting of performance equity, full tax gross-ups on termination).
- Clawback and Change-in-Control: New agreements include clawback requirements and double-trigger change-in-control provisions to align with current laws.
- Severance Terms:
- CFO: 1.5x base salary severance upon termination without cause/change of control.
- EVPs and Division President: 1x base salary severance.
- 2017 Bonus Plan: A new plan was approved covering bonuses earned through March 31, 2017, with potential annual bonuses ranging from $62,500 to $150,000 depending on the role.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance: The filing contains no specific financial guidance or revenue outlook. It notes that the 2017 bonus plan is based on the Compensation Committee's assessment of performance against target goals.
Risks and Contingencies:
- Forward-Looking Statements: The report includes standard disclaimers that actual results may differ materially from expectations due to risks discussed in the Form 10-K.
- Employment Contingencies: Severance and bonus payments are contingent upon executives executing a general release of claims, resigning from directorships, returning company property, and complying with non-competition and non-solicitation provisions (2-year post-termination restriction).
- Repayment Clauses: Specific agreements (e.g., Jeffrey Day) allow the company to demand repayment of severance if non-competition or confidentiality provisions are violated.
Important Facts for Investor Verification
- Verify the total dilution impact of the stock awards and options granted on November 30, 2016 (approx. 26,305 shares in bonuses + 100,000 options).
- Confirm the financial impact of the $22 million Mexico business sale referenced as a basis for executive bonuses.
- Review the full text of Exhibits 10.1 through 10.4 for specific legal definitions of "termination without cause" and "good reason."
- Note the discrepancy in the request metadata: The filing is for Oculus Innovative Sciences, Inc., not Sonoma Pharmaceuticals, Inc.
- Assess the cash outflow for immediate tax gross-ups totaling $50,800 ($6,800 + $30,000 + $9,000 + $5,000).